Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05514717 | A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | PHASE1 | RECRUITING | 162 | — | — | Jan 24, 2023 | Apr 1, 2027 | Jul 11, 2025 | 14 | United States |
Determine the maximum tolerated dose (MTD) of XMT-2056
Assess the safety and tolerability of XMT-2056 by determining the number of patients with adverse events from date of first dose to 30 days post last dose.
The percentage of patients with a best overall response of confirmed complete or partial response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
| Arm | Type | Description |
|---|---|---|
| XMT-2056 | EXPERIMENTAL | XMT-2056 alone (monotherapy) |
| Name | Type | Description |
|---|---|---|
| XMT-2056 | DRUG | XMT-2056 will be administered through a vein in your arm or port catheter (intravenously) |
Inclusion Criteria: * Participant has recurrent or metastatic solid tumors with HER2 expression and has disease progression after treatment, is intolerant to treatment, or is contraindicated with available anti-cancer therapies known to confer benefit, based on investigator's judgement. Note: Parti...